Key facts
- This page summarizes Jason Haas's Form 4 filing for Syros Pharmaceuticals, Inc. (SYRS).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Nov 2024, 17:01.
Jason Haas - 31 Oct 2024 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- SYRS
- Reported as of
- 31 Oct 2024
- Net transaction value
- -$11,754
- SEC form
- 4
- Accepted by SEC
- 04 Nov 2024, 17:01:22 UTC
- Prior SEC filing
- 12 Sep 2024
- Next SEC filing
- 20 Nov 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Todd Rosenthal, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jason Haas filed Form 4 for Syros Pharmaceuticals, Inc. (SYRS) on 04 Nov 2024.
Change
- Previous filing in this sequence was filed on 12 Sep 2024.
- Current net transaction value: -$11,754.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SYRS
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +18,875
- Change %
- +15%
- Price
- Shares after
- 143,427
- Date
- 31 Oct 2024
- Ownership
- Direct
- Footnotes
- F1
SYRS
transaction
Common Stock
Tax liability
- Transaction value
- $11,754
- Shares
- -5,624
- Change %
- -3.9%
- Price
- $2.09
- Shares after
- 137,803
- Date
- 31 Oct 2024
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SYRS
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -18,875
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 31 Oct 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 18,875
- Exercise price
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
Represents shares of common stock received upon vesting of a restricted stock unit award.
Footnote F2
Represents shares used to cover tax withholding on a restricted stock unit release.
Footnote F3
Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
Footnote F4
Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024.